Health Canada approves ZOLADEX® LA for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women. Press Release | May 7th, 2024
Goserelin Dosing Options Included in the National Comprehensive Cancer Network® (NCCN) Breast Cancer Guidelines Press Release | February 5, 2024
Goserelin Included in the National Comprehensive Cancer Network® (NCCN) Head and Neck Cancer Guidelines Press Release | October 24, 2023
TerSera® Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo® (Telotristat Ethyl): Long-Term Registry Trial of Patients with Carcinoid Syndrome Diarrhea Press Release | November 9, 2021
TerSera® Announces Publication of Real-World Study on Xermelo® (Telotristat Ethyl) in Patients with Carcinoid Syndrome Diarrhea Press Release | October 27, 2021
TerSera® Presents Data on Cetirizine HCl Injection (QUZYTTIR®) in the Prevention of Hypersensitivity Infusion Reactions in Patients with Breast Cancer and Other Malignancies Press Release | March 5, 2021
TerSera® Announces Addition of Cetirizine as an Adjunctive Treatment to Interim CDC Guidelines for Managing Adverse Reactions After COVID-19 Vaccination Press Release | February 23, 2021
Lexicon Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Xermelo Press Release | July 30, 2020
Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt Press Release | July 29, 2018
TESARO Enters Asset Purchase Agreement with TerSera® Therapeutics LLC for VARUBI® in the U.S. and Canada Press Release | June 28, 2018